FDA: Abbott failed to reveal facts about Prism

Share this article:
The FDA says product information sheets, a launch presentation and a customer letter for Abbott’s Prism HBsAg (antibody to hepatitis B surface antigen [mouse monoclonal IgM]) and Prism HBcore (hepatitis B virus core antigen [E. coli, [recombinant]) were false and misleading because they failed to reveal facts on important risks associated with the products.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.